Effects of anticoagulant strategies on activation of inflammation and coagulation

Bibliography

• DEMPFLE CE: Coagulopathy of sepsis. Thromb. Haemost. (2004) 91:213-224.
   PubMed Web of Science ®Google Scholar
• ANGUS DC, LINDE-ZWIRBLE WT, LIDICKER J et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. (2001) 29:1303-1310.
   PubMed Web of Science ®Google Scholar
• GERLACH H, KEH D: Sepsis in 2003: are we still in the middle of nowhere? Curr. Opin. Anaesthesiol. (2004) 17:97-106.
   PubMed Web of Science ®Google Scholar
• VAN GESTEL A, BAKKER J, VERAART CP et al.: Prevalence and incidence of severe sepsis in Dutch intensive care units. Crit Care. (2004) 8:R153-R162.
   PubMed Web of Science ®Google Scholar
• HARRISON DA, WELCH CA, EDDLESTON JM: The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care. (2006) 10:R42
   PubMed Web of Science ®Google Scholar
• VAN TILL JW, LEVI M, BRESSER P et al.: Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis. J. Infect. Dis. (2006) 194:1331-1339.
   PubMed Web of Science ®Google Scholar
• COLLINS PW, MACCHIAVELLO LI, LEWIS SJ et al.: Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br. J. Haematol. (2006) 135:220-227.
   PubMed Web of Science ®Google Scholar
• GONANO C, SITZWOHL C, MEITNER E et al.: Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis. Crit Care. (2006) 10:R160
   PubMedGoogle Scholar
• ONTACHI Y, ASAKURA H, TAKAHASHI Y et al.: No interplay between the pathways mediating coagulation and inflammation in tissue factor-induced disseminated intravascular coagulation in rats. Crit Care Med. (2006) 34:2646-2650.
   PubMed Web of Science ®Google Scholar
• CRUZ-TOPETE D, IWAKI T, PLOPLIS VA et al.: Delayed inflammatory responses to endotoxin in fibrinogen-deficient mice. J. Pathol. (2006) 210:325-333.
   PubMed Web of Science ®Google Scholar
• SAITO H, MARUYAMA I, SHIMAZAKI S et al.: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a Phase III, randomized, double-blind clinical trial. J. Thromb. Haemost. (2007) 5:31-41.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, VINCENT JL, LATERRE PF et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. (2001) 344:699-709.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, REINHART K, OPAL S et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. (2003) 290:238-247.
   PubMed Web of Science ®Google Scholar
• WARREN BL, EID A, SINGER P et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. (2001) 286:1869-1878.
   PubMed Web of Science ®Google Scholar
• ESMON CT: Inflammation and the activated protein C anticoagulant pathway. Semin. Thromb. Hemost. (2006) 32 Suppl. 1:49-60.
   Google Scholar
• STEARNS-KUROSAWA DJ, KUROSAWA S, MOLLICA JS et al.: The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. USA (1996) 93:10212-10216.
   PubMed Web of Science ®Google Scholar
• LIAW PC, ESMON CT, KAHNAMOUI K et al.: Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood. (2004) 104:3958-3964.
   PubMed Web of Science ®Google Scholar
• FISHER CJ, JR., YAN SB: Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med. (2000) 28:S49-S56.
   PubMed Web of Science ®Google Scholar
• MOORE KL, ANDREOLI SP, ESMON NL et al.: Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J. Clin. Invest. (1987) 79:124-130.
   PubMed Web of Science ®Google Scholar
• CONWAY EM, ROSENBERG RD: Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol. Cell Biol. (1988) 8:5588-5592.
   PubMed Web of Science ®Google Scholar
• XU J, QU D, ESMON NL et al.: Metalloproteolytic release of endothelial cell protein C receptor. J. Biol. Chem. (2000) 275:6038-6044.
   PubMed Web of Science ®Google Scholar
• ARCHIPOFF G, BERETZ A, FREYSSINET JM et al.: Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem. J. (1991) 273 ( Pt 3):679-684.
   PubMed Web of Science ®Google Scholar
• GLASER CB, MORSER J, CLARKE JH et al.: Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J. Clin. Invest. (1992) 90:2565-2573.
   PubMed Web of Science ®Google Scholar
• FAUST SN, LEVIN M, HARRISON OB et al.: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N. Engl. J. Med. (2001) 345:408-416.
   PubMed Web of Science ®Google Scholar
• MOSNIER LO, GRIFFIN JH: Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci. (2006) 11:2381-2399.
   PubMed Web of Science ®Google Scholar
• STRUKOVA S: Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis. Front Biosci. (2006) 11:59-80.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, MARGOLIS BD, SHANIES HM et al.: Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, Phase IIIB, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest. (2004) 125:2206-2216.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, LATERRE PF, GARG R et al.: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. (2005) 353:1332-1341.
   PubMed Web of Science ®Google Scholar
• TAYLOR FB, JR., CHANG A, ESMON CT et al.: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest. (1987) 79:918-925.
   PubMed Web of Science ®Google Scholar
• HATAJI O, TAGUCHI O, GABAZZA EC et al.: Activation of protein C pathway in the airways. Lung. (2002) 180:47-59.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, OKAJIMA K, UCHIBA M et al.: Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am. J. Physiol. (1997) 272:L197-L202.
   PubMed Web of Science ®Google Scholar
• STURN DH, KANEIDER NC, FEISTRITZER C et al.: Expression and function of the endothelial protein C receptor in human neutrophils. Blood. (2003) 102:1499-1505.
   PubMed Web of Science ®Google Scholar
• FEISTRITZER C, MOSHEIMER BA, STURN DH et al.: Endothelial protein C receptor-dependent inhibition of migration of human lymphocytes by protein C involves epidermal growth factor receptor. J. Immunol. (2006) 176:1019-1025.
   PubMed Web of Science ®Google Scholar
• FEISTRITZER C, STURN DH, KANEIDER NC et al.: Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J. Allergy Clin. Immunol. (2003) 112:375-381.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, OKAJIMA K, UCHIBA M et al.: Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. (1996) 87:642-647.
   PubMed Web of Science ®Google Scholar
• NICK JA, COLDREN CD, GERACI MW et al.: Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. (2004) 104:3878-3885.
   PubMed Web of Science ®Google Scholar
• WARE LB, FANG X, MATTHAY MA: Protein C and thrombomodulin in human acute lung injury. Am. J. Physiol Lung Cell Mol. Physiol. (2003) 285:L514-L521.
   PubMed Web of Science ®Google Scholar
• MAYBAUER MO, MAYBAUER DM, FRASER JF et al.: Recombinant human activated protein C improves pulmonary function in ovine acute lung injury resulting from smoke inhalation and sepsis. Crit Care Med. (2006) 34:2432-2438.
   PubMed Web of Science ®Google Scholar
• YASUI H, GABAZZA EC, TAGUCHI O et al.: Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clin. Appl. Thromb. Hemost. (2000) 6:202-205.
   PubMed Web of Science ®Google Scholar
• YASUI H, GABAZZA EC, TAMAKI S et al.: Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am. J. Respir. Crit Care Med. (2001) 163:1660-1668.
   PubMed Web of Science ®Google Scholar
• SHIMIZU S, GABAZZA EC, TAGUCHI O et al.: Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am. J. Respir. Crit Care Med. (2003) 167:1416-1426.
   PubMed Web of Science ®Google Scholar
• YUDA H, ADACHI Y, TAGUCHI O et al.: Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood. (2004) 103:2196-2204.
   PubMed Web of Science ®Google Scholar
• HOFFMANN JN, VOLLMAR B, LASCHKE MW et al.: Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med. (2004) 32:1011-1017.
   PubMed Web of Science ®Google Scholar
• SCHOOTS IG, LEVI M, VAN VLIET AK et al.: Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med. (2004) 32:1375-1383.
   PubMed Web of Science ®Google Scholar
• ISOBE H, OKAJIMA K, HARADA N et al.: Activated protein C reduces stress-induced gastric mucosal injury in rats by inhibiting the endothelial cell injury. J. Thromb. Haemost. (2004) 2:313-320.
   PubMed Web of Science ®Google Scholar
• MIZUTANI A, OKAJIMA K, UCHIBA M et al.: Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood. (2000) 95:3781-3787.
   PubMed Web of Science ®Google Scholar
• UCHIBA M, OKAJIMA K, OIKE Y et al.: Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ. Res. (2004) 95:34-41.
   PubMed Web of Science ®Google Scholar
• HIROSE K, OKAJIMA K, TAOKA Y et al.: Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann. Surg. (2000) 232:272-280.
   PubMed Web of Science ®Google Scholar
• TAOKA Y, OKAJIMA K, UCHIBA M et al.: Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes. J. Neurosci. (1998) 18:1393-1398.
   PubMed Web of Science ®Google Scholar
• FOLSOM AR, ROSAMOND WD, SHAHAR E et al.: Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. (1999) 100:736-742.
   PubMed Web of Science ®Google Scholar
• CHENG T, LIU D, GRIFFIN JH et al.: Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. (2003) 9:338-342.
   PubMed Web of Science ®Google Scholar
• SHIBATA M, KUMAR SR, AMAR A et al.: Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation. (2001) 103:1799-1805.
   PubMed Web of Science ®Google Scholar
• ZLOKOVIC BV, ZHANG C, LIU D et al.: Functional recovery after embolic stroke in rodents by activated protein C. Ann. Neurol. (2005) 58:474-477.
   PubMed Web of Science ®Google Scholar
• GUO H, LIU D, GELBARD H et al.: Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron. (2004) 41:563-572.
   PubMed Web of Science ®Google Scholar
• LIU D, CHENG T, GUO H et al.: Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat. Med. (2004) 10:1379-1383.
   PubMed Web of Science ®Google Scholar
• CHENG T, PETRAGLIA AL, LI Z et al.: Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat. Med. (2006) 12:1278-1285.
   PubMed Web of Science ®Google Scholar
• FEISTRITZER C, LENTA R, RIEWALD M: Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in Factor Xa signaling. J. Thromb. Haemost. (2005) 3:2798-2805.
   PubMed Web of Science ®Google Scholar
• FEISTRITZER C, RIEWALD M: Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. (2005) 105:3178-3184.
   PubMed Web of Science ®Google Scholar
• FINIGAN JH, DUDEK SM, SINGLETON PA et al.: Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J. Biol. Chem. (2005) 280:17286-17293.
   PubMed Web of Science ®Google Scholar
• ZENG W, MATTER WF, YAN SB et al.: Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med. (2004) 32:S302-S308.
   PubMedGoogle Scholar
• GREY ST, TSUCHIDA A, HAU H et al.: Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J. Immunol. (1994) 153:3664-3672.
   PubMed Web of Science ®Google Scholar
• WHITE B, SCHMIDT M, MURPHY C et al.: Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br. J. Haematol. (2000) 110:130-134.
   PubMed Web of Science ®Google Scholar
• YUKSEL M, OKAJIMA K, UCHIBA M et al.: Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb. Haemost. (2002) 88:267-273.
   PubMed Web of Science ®Google Scholar
• RIEWALD M, PETROVAN RJ, DONNER A et al.: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. (2002) 296:1880-1882.
   PubMed Web of Science ®Google Scholar
• ESMON CT: Is APC activation of endothelial cell PAR1 important in severe sepsis?: No. J. Thromb. Haemost. (2005) 3:1910-1911.
   PubMed Web of Science ®Google Scholar
• RUF W: Is APC activation of endothelial cell PAR1 important in severe sepsis?: Yes. J. Thromb. Haemost. (2005) 3:1912-1914.
   PubMed Web of Science ®Google Scholar
• JOYCE DE, GELBERT L, CIACCIA A et al.: Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. (2001) 276:11199-11203.
   PubMed Web of Science ®Google Scholar
• RIEWALD M, RUF W: Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J. Biol. Chem. (2005) 280:19808-19814.
   PubMed Web of Science ®Google Scholar
• JOYCE DE, GRINNELL BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med. (2002) 30:S288-S293.
   PubMed Web of Science ®Google Scholar
• FRANSCINI N, BACHLI EB, BLAU N et al.: Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation. (2004) 110:2903-2909.
   PubMed Web of Science ®Google Scholar
• JACKSON CJ, XUE M, THOMPSON P et al.: Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound. Repair Regen. (2005) 13:284-294.
   PubMed Web of Science ®Google Scholar
• HOOPER WC, PHILLIPS DJ, RENSHAW MA et al.: The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C. J. Immunol. (1998) 161:2567-2573.
   PubMed Web of Science ®Google Scholar
• HOOPER WC, PHILLIPS DJ, RENSHAW MA: Activated protein C induction of MCP-1 in human endothelial cells: a possible role for endothelial cell nitric oxide synthase. Thromb. Res. (2001) 103:209-219.
   PubMed Web of Science ®Google Scholar
• FEISTRITZER C, SCHUEPBACH RA, MOSNIER LO et al.: Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J. Biol. Chem. (2006) 281:20077-20084.
   PubMed Web of Science ®Google Scholar
• BOATRIGHT KM, SALVESEN GS: Mechanisms of caspase activation. Curr. Opin. Cell Biol. (2003) 15:725-731.
   PubMed Web of Science ®Google Scholar
• REED JC: Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death. Differ. (2006) 13:1378-1386.
   PubMed Web of Science ®Google Scholar
• GREEN DR: Apoptotic pathways: ten minutes to dead. Cell. (2005) 121:671-674.
   PubMed Web of Science ®Google Scholar
• HOTCHKISS RS, CHANG KC, SWANSON PE et al.: Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. (2000) 1:496-501.
   PubMed Web of Science ®Google Scholar
• MOREL N, MOREL O, DELABRANCHE X et al.: [Microparticles during sepsis and trauma. A link between inflammation and thrombotic processes]. Ann. Fr. Anesth. Reanim. (2006) 25:955-966.
   PubMed Web of Science ®Google Scholar
• MOSNIER LO, GRIFFIN JH: Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem. J. (2003) 373:65-70.
   PubMed Web of Science ®Google Scholar
• STEPHENSON DA, TOLTL LJ, BEAUDIN S et al.: Modulation of monocyte function by activated protein C, a natural anticoagulant. J. Immunol. (2006) 177:2115-2122.
   PubMed Web of Science ®Google Scholar
• SHUA F, KOBAYASHIA H, FUKUDOMEB K et al.: Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett. (2000) 477:208-212.
   PubMed Web of Science ®Google Scholar
• JOYCE DE, NELSON DR, GRINNELL BW: Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit Care Med. (2004) 32:S280-S286.
   PubMedGoogle Scholar
• GALLIGAN L, LIVINGSTONE W, VOLKOV Y et al.: Characterization of protein C receptor expression in monocytes. Br. J. Haematol. (2001) 115:408-414.
   PubMed Web of Science ®Google Scholar
• BRUECKMANN M, HOFFMANN U, DE ROSSI L et al.: Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes. Cytokine. (2004) 26:106-113.
   PubMed Web of Science ®Google Scholar
• KALIL AC, COYLE SM, UM JY et al.: Effects of drotrecogin alfa (activated) in human endotoxemia. Shock. (2004) 21:222-229.
   PubMed Web of Science ®Google Scholar
• HANCOCK WW, GREY ST, HAU L et al.: Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation. (1995) 60:1525-1532.
   PubMed Web of Science ®Google Scholar
• LIAW PC, NEUENSCHWANDER PF, SMIRNOV MD et al.: Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J. Biol. Chem. (2000) 275:5447-5452.
   PubMed Web of Science ®Google Scholar
• KUROSAWA S, STEARNS-KUROSAWA DJ, CARSON CW et al.: Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood. (1998) 91:725-727.
   PubMed Web of Science ®Google Scholar
• KUROSAWA S, STEARNS-KUROSAWA DJ, HIDARI N et al.: Identification of functional endothelial protein C receptor in human plasma. J. Clin. Invest. (1997) 100:411-418.
   PubMed Web of Science ®Google Scholar
• KUROSAWA S, ESMON CT, STEARNS-KUROSAWA DJ: The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J. Immunol. (2000) 165:4697-4703.
   PubMed Web of Science ®Google Scholar
• ESMON CT: Coagulation and inflammation. J. Endotoxin. Res. (2003) 9:192-198.
   PubMedGoogle Scholar
• ROSENBERG RD, BAUER KA: Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S. Hum. Pathol. (1987) 18:253-262.
   PubMed Web of Science ®Google Scholar
• ANDERSSON LO, ENGMAN L, HENNINGSSON E: Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III-thrombin complex. J. Immunol. Methods. (1977) 14:271-281.
   PubMed Web of Science ®Google Scholar
• PERLMUTTER DH, GLOVER GI, RIVETNA M et al.: Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc. Natl. Acad. Sci. USA (1990) 87:3753-3757.
   PubMed Web of Science ®Google Scholar
• PIZZO SV: Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am. J. Med. (1989) 87:10S-14S.
   PubMed Web of Science ®Google Scholar
• BOMBELI T, MUELLER M, HAEBERLI A: Anticoagulant properties of the vascular endothelium. Thromb. Haemost. (1997) 77:408-423.
   PubMed Web of Science ®Google Scholar
• HAUPTMAN JG, HASSOUNA HI, BELL TG et al.: Efficacy of antithrombin III in endotoxin-induced disseminated intravascular coagulation. Circ. Shock. (1988) 25:111-122.
   PubMedGoogle Scholar
• MAMMEN EF, MIYAKAWA T, PHILLIPS TF et al.: Human antithrombin concentrates and experimental disseminated intravascular coagulation. Semin. Thromb. Hemost. (1985) 11:373-383.
   PubMed Web of Science ®Google Scholar
• DE JONGE E, LEVI M, STOUTENBEEK CP et al.: Current drug treatment strategies for disseminated intravascular coagulation. Drugs. (1998) 55:767-777.
   PubMed Web of Science ®Google Scholar
• SCHREGEL W, STRAUB H, WOLK G et al.: [Successful therapy of consumption coagulopathy in EPH gestosis with multiple organ failure]. Anasth. Intensivther. Notfallmed. (1984) 19:201-203.
   PubMedGoogle Scholar
• DICKNEITE G, PAQUES EP: Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb. Haemost. (1993) 69:98-102.
   PubMed Web of Science ®Google Scholar
• EMERSON TE, JR., FOURNEL MA, LEACH WJ et al.: Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat. Circ. Shock. (1987) 21:1-13.
   PubMedGoogle Scholar
• RONNEBERGER H, HEIN B: [Effect of antithrombin III on experimental hepatotoxin poisoning in dogs]. Arzneimittelforschung. (1984) 34:277-279.
   PubMed Web of Science ®Google Scholar
• TAYLOR FB, JR., EMERSON TE, JR., JORDAN R et al.: Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ. Shock. (1988) 26:227-235.
   PubMedGoogle Scholar
• BAUDO F, CAIMI TM, DE CATALDO F et al.: Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. (1998) 24:336-342.
   PubMed Web of Science ®Google Scholar
• EISELE B, LAMY M, THIJS LG et al.: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. (1998) 24:663-672.
   PubMed Web of Science ®Google Scholar
• FOURRIER F, CHOPIN C, HUART JJ et al.: Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. (1993) 104:882-888.
   PubMed Web of Science ®Google Scholar
• INTHORN D, HOFFMANN JN, HARTL WH et al.: Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock. (1998) 10:90-96.
   PubMed Web of Science ®Google Scholar
• VINAZZER H: Clinical use of antithrombin III concentrates. Vox Sang. (1987) 53:193-198.
   PubMed Web of Science ®Google Scholar
• REZAIE AR: Determinants of specificity of factor xa interaction with its physiological inhibitors. Mini. Rev. Med. Chem. (2006) 6:859-865.
   PubMed Web of Science ®Google Scholar
• YANG L, MANITHODY C, REZAIE AR: Heparin-activated antithrombin interacts with the autolysis loop of target coagulation proteases. Blood. (2004) 104:1753-1759.
   PubMed Web of Science ®Google Scholar
• RIEWALD M, KRAVCHENKO VV, PETROVAN RJ et al.: Gene induction by coagulation Factor Xa is mediated by activation of protease-activated receptor 1. Blood. (2001) 97:3109-3116.
   PubMed Web of Science ®Google Scholar
• COUGHLIN SR: How the protease thrombin talks to cells. Proc. Natl. Acad. Sci. USA (1999) 96:11023-11027.
   PubMed Web of Science ®Google Scholar
• TAYLOR FB, JR., CHANG AC, PEER GT et al.: DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood. (1991) 78:364-368.
   PubMed Web of Science ®Google Scholar
• YAMAUCHI T, UMEDA F, INOGUCHI T et al.: Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem. Biophys. Res. Commun. (1989) 163:1404-1411.
   PubMed Web of Science ®Google Scholar
• HOXIE JA, AHUJA M, BELMONTE E et al.: Internalization and recycling of activated thrombin receptors. J. Biol. Chem. (1993) 268:13756-13763.
   PubMed Web of Science ®Google Scholar
• HARADA N, OKAJIMA K, KUSHIMOTO S et al.: Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood. (1999) 93:157-164.
   PubMed Web of Science ®Google Scholar
• UCHIBA M, OKAJIMA K, KAUN C et al.: Inhibition of the endothelial cell activation by antithrombin in vitro. Thromb. Haemost. (2004) 92:1420-1427.
   PubMed Web of Science ®Google Scholar
• OSTROVSKY L, WOODMAN RC, PAYNE D et al.: Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. (1997) 96:2302-2310.
   PubMed Web of Science ®Google Scholar
• HOFFMANN JN, VOLLMAR B, INTHORN D et al.: Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am. J. Physiol Cell Physiol. (2000) 279:C98-C107.
   PubMed Web of Science ®Google Scholar
• NEVIERE R, TOURNOYS A, MORDON S et al.: Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock. (2001) 15:220-225.
   PubMed Web of Science ®Google Scholar
• MIZUTANI A, OKAJIMA K, UCHIBA M et al.: Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood. (2003) 101:3029-3036.
   PubMed Web of Science ®Google Scholar
• HARADA N, OKAJIMA K, UCHIBA M et al.: Antithrombin reduces ischemia/reperfusion-induced liver injury in rats by activation of cyclooxygenase-1. Thromb. Haemost. (2004) 92:550-558.
   PubMed Web of Science ®Google Scholar
• HIROSE K, OKAJIMA K, UCHIBA M et al.: Antithrombin reduces the ischemia/reperfusion-induced spinal cord injury in rats by attenuating inflammatory responses. Thromb. Haemost. (2004) 91:162-170.
   PubMed Web of Science ®Google Scholar
• TAOKA Y, OKAJIMA K, UCHIBA M: Antithrombin reduces compression-induced spinal cord injury in rats. J. Neurotrauma. (2004) 21:1818-1830.
   PubMed Web of Science ®Google Scholar
• AYTEKIN FO, TEKIN K, KABAY B et al.: Antithrombin III attenuates pulmonary tissue injury caused by mesenteric ischemia-reperfusion. Am. J. Surg. (2005) 189:161-166.
   PubMed Web of Science ®Google Scholar
• TEKIN K, AYTEKIN F, OZDEN A et al.: Antithrombin III prevents deleterious effects of remote ischemia-reperfusion injury on healing of colonic anastomoses. Am. J. Surg. (2002) 184:160-165.
   PubMed Web of Science ®Google Scholar
• HARADA N, OKAJIMA K, YUKSEL M et al.: Contribution of capsaicin-sensitive sensory neurons to antithrombin-induced reduction of ischemia/reperfusion-induced liver injury in rats. Thromb. Haemost. (2005) 93:48-56.
   PubMed Web of Science ®Google Scholar
• JORMALAINEN M, VENTO AE, WARTIOVAARA-KAUTTO U et al.: Antithrombin reduces pulmonary hypertension during reperfusion after cardiopulmonary bypass in a pig. Acta Anaesthesiol. Scand. (2006)
   PubMedGoogle Scholar
• HOFFMANN JN, VOLLMAR B, LASCHKE MW et al.: Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb. Haemost. (2002) 88:242-252.
   PubMed Web of Science ®Google Scholar
• VAN VEEN SQ, CHEUNG CW, MEIJERS JC et al.: Anticoagulant and anti-inflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis. J. Thromb. Haemost. (2006) 4:2343-2351.
   PubMed Web of Science ®Google Scholar
• DUNZENDORFER S, KANEIDER N, RABENSTEINER A et al.: Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood. (2001) 97:1079-1085.
   PubMed Web of Science ®Google Scholar
• KANEIDER NC, EGGER P, DUNZENDORFER S et al.: Syndecan-4 as antithrombin receptor of human neutrophils. Biochem. Biophys. Res. Commun. (2001) 287:42-46.
   PubMed Web of Science ®Google Scholar
• KANEIDER NC, REINISCH CM, DUNZENDORFER S et al.: Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J. Cell Sci. (2002) 115:227-236.
   PubMed Web of Science ®Google Scholar
• FEISTRITZER C, KANEIDER NC, STURN DH et al.: Syndecan-4-dependent migration of human eosinophils. Clin. Exp. Allergy. (2004) 34:696-703.
   PubMed Web of Science ®Google Scholar
• HORIE S, ISHII H, KAZAMA M: Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb. Res. (1990) 59:895-904.
   PubMed Web of Science ®Google Scholar
• OLSON ST, BJORK I, SHEFFER R et al.: Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. (1992) 267:12528-12538.
   PubMed Web of Science ®Google Scholar
• ISHIGURO K, KOJIMA T, MURAMATSU T: Syndecan-4 as a molecule involved in defense mechanisms. Glycoconj. J. (2002) 19:315-318.
   PubMed Web of Science ®Google Scholar
• KANEIDER NC, FORSTER E, MOSHEIMER B et al.: Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thromb. Haemost. (2003) 90:1150-1157.
   PubMed Web of Science ®Google Scholar
• OELSCHLAGER C, ROMISCH J, STAUBITZ A et al.: Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood. (2002) 99:4015-4020.
   PubMed Web of Science ®Google Scholar
• MANSELL A, REINICKE A, WORRALL DM et al.: The serine protease inhibitor antithrombin III inhibits LPS-mediated NF-kappaB activation by TLR-4. FEBS Lett. (2001) 508:313-317.
   PubMed Web of Science ®Google Scholar
• HATADA EN, KRAPPMANN D, SCHEIDEREIT C: NF-kappaB and the innate immune response. Curr. Opin. Immunol. (2000) 12:52-58.
   PubMed Web of Science ®Google Scholar
• MINNEMA MC, CHANG AC, JANSEN PM et al.: Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. (2000) 95:1117-1123.
   PubMed Web of Science ®Google Scholar
• SOUTER PJ, THOMAS S, HUBBARD AR et al.: Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med. (2001) 29:134-139.
   PubMed Web of Science ®Google Scholar
• GRITTI D, MALINVERNO A, GASPARETTO C et al.: Attenuation of leukocyte beta 2-integrin expression by antithrombin-III. Int. J. Immunopathol. Pharmacol. (2004) 17:27-32.
   PubMed Web of Science ®Google Scholar
• GEIBEN-LYNN R, BROWN N, WALKER BD et al.: Purification of a modified form of bovine antithrombin III as an HIV-1 CD8+ T-cell antiviral factor. J. Biol. Chem. (2002) 277:42352-42357.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, PIRIE-SHEPHERD S, LANE WS et al.: Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. (1999) 285:1926-1928.
   PubMed Web of Science ®Google Scholar
• LARSSON H, AKERUD P, NORDLING K et al.: A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J. Biol. Chem. (2001) 276:11996-12002.
   PubMed Web of Science ®Google Scholar
• LARSSON H, SJOBLOM T, DIXELIUS J et al.: Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res. (2000) 60:6723-6729.
   PubMed Web of Science ®Google Scholar
• PROX D, BECKER C, PIRIE-SHEPHERD SR et al.: Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J. Surg. (2003) 27:405-411.
   PubMed Web of Science ®Google Scholar
• ZHANG W, CHUANG YJ, JIN T et al.: Antiangiogenic antithrombin induces global changes in the gene expression profile of endothelial cells. Cancer Res. (2006) 66:5047-5055.
   PubMed Web of Science ®Google Scholar
• ZHANG W, CHUANG YJ, SWANSON R et al.: Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells. Blood. (2004) 103:1185-1191.
   PubMed Web of Science ®Google Scholar
• ZHANG W, SWANSON R, IZAGUIRRE G et al.: The heparin-binding site of antithrombin is crucial for antiangiogenic activity. Blood. (2005) 106:1621-1628.
   PubMed Web of Science ®Google Scholar
• GANDO S, SAWAMURA A, HAYAKAWA M et al.: First day dynamic changes in antithrombin III activity after supplementation have a predictive value in critically ill patients. Am. J. Hematol. (2006) 81:907-914.
   PubMed Web of Science ®Google Scholar
• BLAUHUT B, KRAMAR H, VINAZZER H et al.: Substitution of antithrombin III in shock and DIC: a randomized study. Thromb. Res. (1985) 39:81-89.
   PubMed Web of Science ®Google Scholar
• KIENAST J, JUERS M, WIEDERMANN CJ et al.: Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J. Thromb. Haemost. (2006) 4:90-97.
   PubMed Web of Science ®Google Scholar
• VINAZZER HA: Antithrombin III in shock and disseminated intravascular coagulation. Clinical and Applied Thrombosis-Hemostasis. (1995) 1:62-65.
   Web of Science ®Google Scholar
• LEITNER JM, FIRBAS C, MAYR FB et al.: Recombinant human antithrombin inhibits thrombin formation and interleukin 6 release in human endotoxemia. Clin. Pharmacol. Ther. (2006) 79:23-34.
   PubMed Web of Science ®Google Scholar
• WIEDERMANN CJ, KANEIDER NC: A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis. Blood Coagul. Fibrinolysis. (2006) 17:521-526.
   PubMed Web of Science ®Google Scholar
• MOSNIER LO, GALE AJ, YEGNESWARAN S et al.: Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. (2004) 104:1740-1744.
   PubMed Web of Science ®Google Scholar